Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases

Summary

The goal of this clinical research study is to learn more about how the study drug alpharadin (Radium-223) works in patients who have CPRC that has spread to the bone.

Timeline

Start

2014-09-19

Primary completion

2020-11-11

Completion

2020-11-11

Publications

• Corn PG, Yu G, Fan Y, Zhang M, Troncoso P, Surasi DS, Liu S, Ajani JA, Logothetis CJ, Wang G, Panaretakis T, Lin SH. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis. 2025 Dec 26. doi: 10.1038/s41391-025-01069-1. Online ahead of print.

Drugs

Indications